Roland Diel1, Robert Loddenkemper2, Albert Nienhaus3. 1. Department of Pulmonary Medicine, Medical School Hannover (MHH), Hannover, Institute for Health Service Research in Dermatology and Nursing, Hamburg, Germany. Electronic address: Diel.Roland@mh-hannover.de. 2. The German Central Committee Against Tuberculosis, Berlin, Institute for Health Service Research in Dermatology and Nursing, Hamburg, Germany. 3. University Medical Center Hamburg-Eppendorf, Institute for Health Service Research in Dermatology and Nursing, Hamburg, Germany.
Abstract
BACKGROUND: Given the current lack of effective vaccines against TB, the accuracy of screening tests for determining or excluding latent TB infection (LTBI) is decisive in effective TB control. This meta-analysis critically appraises studies investigating the positive and the negative predictive value (PPV and NPV, respectively) from a test-determined LTBI state for progression to active TB of interferon-γ release assays (IGRAs) and the tuberculin skin test (TST). METHODS: We searched MEDLINE, EMBASE, and Cochrane bibliographies for relevant articles. After qualitative evaluation, the PPV and NPV for progression of commercial and “in-house” IGRAs and the TST for persons not receiving preventive treatment in the context of the respective IGRA studies were pooled using both a fixed and a random-effect model. Weighted rates were calculated for all study populations and for groups solely at high risk of TB development. RESULTS: The pooled PPV for progression for all studies using commercial IGRAs was 2.7% (95% CI, 2.3%-3.2%) compared with 1.5% (95% CI, 1.2%-1.7%) for the TST (P < .0001). PPV increased to 6.8% (95% CI, 5.6%-8.3%) and 2.4% (95% CI, 1.9%-2.9%) for the IGRAs and the TST, respectively, when only high-risk groups were considered (P < .0001). Pooled values of NPV for progression for both IGRAs and the TST were very high, at 99.7% (95% CI, 99.5%-99.8%) and 99.4% (95% CI, 99.2%-99.5%), respectively, although they were significantly higher for IGRAs (P < .01). CONCLUSIONS: Commercial IGRAs have a higher PPV and NPV for progression to active TB compared with those of the TST, especially when performed in high-risk persons.
BACKGROUND: Given the current lack of effective vaccines against TB, the accuracy of screening tests for determining or excluding latent TB infection (LTBI) is decisive in effective TB control. This meta-analysis critically appraises studies investigating the positive and the negative predictive value (PPV and NPV, respectively) from a test-determined LTBI state for progression to active TB of interferon-γ release assays (IGRAs) and the tuberculin skin test (TST). METHODS: We searched MEDLINE, EMBASE, and Cochrane bibliographies for relevant articles. After qualitative evaluation, the PPV and NPV for progression of commercial and “in-house” IGRAs and the TST for persons not receiving preventive treatment in the context of the respective IGRA studies were pooled using both a fixed and a random-effect model. Weighted rates were calculated for all study populations and for groups solely at high risk of TB development. RESULTS: The pooled PPV for progression for all studies using commercial IGRAs was 2.7% (95% CI, 2.3%-3.2%) compared with 1.5% (95% CI, 1.2%-1.7%) for the TST (P < .0001). PPV increased to 6.8% (95% CI, 5.6%-8.3%) and 2.4% (95% CI, 1.9%-2.9%) for the IGRAs and the TST, respectively, when only high-risk groups were considered (P < .0001). Pooled values of NPV for progression for both IGRAs and the TST were very high, at 99.7% (95% CI, 99.5%-99.8%) and 99.4% (95% CI, 99.2%-99.5%), respectively, although they were significantly higher for IGRAs (P < .01). CONCLUSIONS: Commercial IGRAs have a higher PPV and NPV for progression to active TB compared with those of the TST, especially when performed in high-risk persons.
Authors: Madeline L Slater; Gary Welland; Madhukar Pai; Julie Parsonnet; Niaz Banaei Journal: Am J Respir Crit Care Med Date: 2013-10-15 Impact factor: 21.405
Authors: Jason R Andrews; Mark Hatherill; Hassan Mahomed; Willem A Hanekom; Monica Campo; Thomas R Hawn; Robin Wood; Thomas J Scriba Journal: Am J Respir Crit Care Med Date: 2015-03-01 Impact factor: 21.405
Authors: Patricio Escalante; Tobias Peikert; Virginia P Van Keulen; Courtney L Erskine; Cathy L Bornhorst; Boleyn R Andrist; Kevin McCoy; Larry R Pease; Roshini S Abraham; Keith L Knutson; Hirohito Kita; Adam G Schrum; Andrew H Limper Journal: Am J Respir Crit Care Med Date: 2015-09-01 Impact factor: 21.405
Authors: Jonathon R Campbell; Wenjia Chen; James Johnston; Victoria Cook; Kevin Elwood; Jane Krot; Fawziah Marra Journal: Mol Diagn Ther Date: 2015-04 Impact factor: 4.074
Authors: L Lebina; P M Abraham; M Milovanovic; K Motlhaoleng; R E Chaisson; M Rakgokong; J Golub; E Variava; N A Martinson Journal: Int J Tuberc Lung Dis Date: 2015-11 Impact factor: 2.373